Glatiramer acetate: A complex drug beyond biologics-Reference-Cited by-同舟云学术

Glatiramer acetate: A complex drug beyond biologics

Published:2019-05 Issue: Volume:133 Page:8-14
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Rocco Paolo^ORCID,Eberini Ivano,Musazzi Umberto M.,Franzè Silvia,Minghetti Paola

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference48 articles.

1. A comprehensive review on Copemyl®;Annovazzi;Neurol. Ther.,2017

2. Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes;Borchard;Expert Opin. Drug Deliv.,2017

3. Equivalence of glatiramer acetate generics with branded glatiramer acetate in efficacy and cost for the treatment of multiple sclerosis;Bourdette;JAMA Neurol.,2015

4. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone;Brenner;J. Neuroimmunol.,2001

5. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis;Carter;Drugs,2010

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploiting Pharma 4.0 Technologies in the Non-Biological Complex Drugs Manufacturing: Innovations and Implications;Pharmaceutics;2023-10-28

2. Feeding Next‐Generation Nanomedicines to Europe: Regulatory and Quality Challenges;Advanced Healthcare Materials;2023-09-17

3. Regulatory considerations for generic products of non-biological complex drugs;Journal of Food and Drug Analysis;2023-03-10

4. Medicinal products meet medical devices: Classification and nomenclature issues arising from their combined use;Drug Discovery Today;2022-10

5. Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators;Journal of Medical Economics;2022-09-28